MEDICURE INC (MCUJF) Form 6-K — Aug 19, 2026
Medicure Inc. filed unaudited Q2 and first-half 2026 results via Form 6-K. Net revenue rose to CAD$7.4 million in Q2 from CAD$6.7 million a year earlier, but the quarterly net loss widened to CAD$1.4 million (CAD$0.14 per share) from CAD$786 thousand (CAD$0.08 per share). The pharmacy segment drove growth, with Marley Drug, Gateway Pharmacy and West Olympia Pharmacy generating CAD$11.6 million of H1 revenue, while ZYPITAMAG sales reached CAD$4.1 million, up from CAD$2.8 million.
Key figures
- Eps
- Q2 2026: CAD$(0.14) basic and diluted (vs CAD$(0.08)); H1 2026: CAD$(0.18) (vs CAD$(0.14))
- Revenue
- Q2 2026: CAD$7,427K (vs CAD$6,669K prior year); H1 2026: CAD$15,374K (vs CAD$12,153K)
- Net Income
- Q2 2026 net loss CAD$(1,428)K (vs CAD$(786)K); H1 2026 net loss CAD$(1,834)K (vs CAD$(1,480)K)
- Total Debt
- 0
- Total Assets
- 22594
- Cash Position
- 1832
- Shares Outstanding
- 10436313
- Currency
- thousands of CAD except per share/where noted
- Gross Profit Q2
- 3198
- Adjusted Ebitda H1
- 452
- Adjusted Ebitda Q2
- 172
- Cms Rebate Liability
- 864
- Aggrastat H1 Net Sales
- CAD$1.6M (vs CAD$3.4M prior year)
- Aggrastat Q2 Net Sales
- CAD$661K (vs CAD$1.7M prior year)
- Insider Voting Control
- 27% (directors and key management)
- Negative Working Capital
- 336
- Zypitamag H1 Total Revenue
- CAD$4.1M (vs CAD$2.8M prior year)
- Pharmacy Segment H1 Revenue
- 11628
- Marketing Distribution H1 Revenue
- 3746
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.